Propanc Biopharma (PPCB) Interest Expenses (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Interest Expenses of $58955.0 for Q4 2025, down 50.43% year-over-year from $118943.0 in Q4 2024, and down 80.71% quarter-over-quarter from $305649.0 in Q3 2025.
Propanc Biopharma (PPCB) Interest Expenses (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Interest Expenses for 15 consecutive years, with $58955.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses fell 50.43% year-over-year to $58955.0; the TTM figure through Dec 2025 stood at $190146.0 (down 55.61% YoY), while the FY2025 annual figure was $23.8 million, up 108.04% from the prior year.
- Interest Expenses slipped to $58955.0 in Q4 2025 per PPCB's latest filing, from $305649.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $10.0 million in Q2 2021 and bottomed at -$278500.0 in Q2 2025.
- Historically, Interest Expenses has averaged $610967.0 across 5 years, with a median of $126042.0 in 2024.
- Annual changes were most pronounced in 2021 — Interest Expenses surged 471.46% — and 2025, when it plunged 409.43%.
- Propanc Biopharma's Interest Expenses stood at $177905.0 in 2021, then tumbled by 44.57% to $98619.0 in 2022, then surged by 168.17% to $264462.0 in 2023, then plunged by 55.02% to $118943.0 in 2024, then tumbled by 50.43% to $58955.0 in 2025.
- Business Quant data shows PPCB's Interest Expenses at $58955.0 in Q4 2025, $305649.0 in Q3 2025, and -$278500.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 58,955.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58,955.00 |
| Dec 31, 2025 | 58,955.00 |
| Sep 30, 2025 | 305,649.00 |
| Sep 30, 2025 | 305,649.00 |
| Jun 30, 2025 | -278,500.00 |
| Jun 30, 2025 | -278,500.00 |
| Mar 31, 2025 | 104,042.00 |
| Mar 31, 2025 | 104,042.00 |
| Dec 31, 2024 | 118,943.00 |
| Dec 31, 2024 | 118,943.00 |
| Sep 30, 2024 | 86,230.00 |
| Sep 30, 2024 | 86,230.00 |
| Jun 30, 2024 | 90,004.00 |
| Jun 30, 2024 | 90,004.00 |
| Mar 31, 2024 | 133,141.00 |
| Mar 31, 2024 | 133,141.00 |
| Dec 31, 2023 | 264,462.00 |
| Dec 31, 2023 | 264,462.00 |
| Sep 30, 2023 | 178,234.00 |
| Sep 30, 2023 | 178,234.00 |